DDInter596 DDInter53
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may lead to a major life threatening interaction when taken with {v} Methadone
Methadone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Doxorubicin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Lurasidone
Lurasidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Niraparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Doxorubicin {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Hepatobiliary disease {u} (Side Effect) is caused by {v} (Compound) Lurasidone
Lurasidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Teriflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Ivosidenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may lead to a major life threatening interaction when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Doxorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound) and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Doxorubicin (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Lurasidone (Compound) and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin (Compound) resembles Epirubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Doxorubicin (Compound) resembles Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib